|
Why Chimerix Pivoted To Take On COVID-19 Rob Wright, chief editor of Life Science Leader, recently conducted a virtual roundtable with three CEOs of publicly traded biopharmaceutical companies (view full video here). In this clip, Mike Sherman, CEO of Chimerix (NASDAQ: CMRX), discusses the decision making behind an R&D pivot and the initiation of a Phase 2/3 study of dociparstat sodium (DSTAT) in acute lung injury for patients with severe COVID-19. https://www.lifescienceleader.com/doc/why-chimerix-pivoted-t… \ud83e\udd14 |
|
| aus der Diskussion: | Chimerix im COVID-19 Jahr |
| Autor (Datum des Eintrages): | Schlood (27.05.20 08:29:27) |
| Beitrag: | 4 von 37 (ID:63813923) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |